Haematologic Parameters in Metastatic Colorectal Cancer Patients Treated with Capecitabine Combination Therapy

Abstract

MCV showed significant increase in chemotherapy response groups (PR and SD). In addition, a significant decrease was observed for platelet count in chemotherapy response groups. While NLR decrease was seen in only a PR group, PCT decrease was observed in all three groups. PCT and PLT values were higher in patients receiving Bevacizumab. Conclusions: PLT, PCT, MPV, and NLR values were decreased due to Capecitabinebased chemotherapy, however MCV was increased. PCT and PLT values were higher in patients who received Bevacizumab than those who did not. MCV, PLT, and NLR can be considered as important factors in predicting response to colorectal carcinoma treatment.

Lack of Prognostic Value of Mean Corpuscular Volume with Capecitabine Therapy in Metastatic Breast Cancer

“…In the study, patients were evaluated after 9 weeks and MCV elevation was found to be higher in the patients with complete and partial response (CR+PR) as compared to the patients with stable and progressive disease (SD+PD). Similar findings for response were noted for colorectal cancer cases (Inanc et al, 2014).However, in the present study, when the patients were grouped in the same manner, no significant difference was determined between the groups in terms of change in MCV. Arslan et al (2011) evaluated 75 metastatic breast cancer patients receiving capecitabine and found the median MCV difference (post-treatment values at nine week-baseline) to be 8.…”

Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer

“…10,12 This situation with different cytokines that have proinflammatory characteristics is very important for cancer patients. [18][19][20][21][22][23][24][25] However, Osada et al 18 reported that increased MPV level was very important in stomach cancer patients in compared with healthy subjects. 10,[12][13][14][15] Some studies did not find a relationship between MPV and platelet count as a prognostic factors in cancer patients.…”

“…10,[12][13][14][15] Some studies did not find a relationship between MPV and platelet count as a prognostic factors in cancer patients. [18][19][20][21][22][23][24][25] However, Osada et al 18 reported that increased MPV level was very important in stomach cancer patients in compared with healthy subjects. Increased MPV in patients with gastric cancer have a relationship with p-selectin, which is an important indicator of platelet activation in thrombocyte surfaces.…”

“…18 Other studies suggested the use of variables (e.g., MPV, platelet count, platelet allocation, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio) from peripheral blood before chirurgical operation or before systemic treatment as an indicator of cancer progression and inflammation in patients with colon, esophageal, ovarian, and breast cancer. [19][20][21][22][23][24] Mutlu et al 26 have indicated that increased MPV have not any significance at time of prognosis or thrombotic event in different types of cancer. 26 Aksoy et al 27 even reported the MPV value decreasing significantly in patients with bone marrow metastasis in comparison with healthy control subjects.…”

A Systemic Analysis on Pemetrexed in Treating Patients with Breast Cancer

“…Breast cancer remains a significant problem for global health as it is one of the most common cause of tumorrelated death world-wide (Fouz et al, 2013;Engin et al, 2013;Sedighi et al, 2013;Zhu et al, 2013;Wu et al , 2014;Cabuk et al, 2014;Chin et al, 2014;Fouladi et al, 2014;Majeed et al, 2014;Gogia et al, 2014;Liu et al, 2014;Louisa et al, 2014;Moazzezy et al, 2014;Niu et al, 2014;Rizalar et al, 2014;Sipetic-Grujicic et al, 2014;Prajoko et al, 2014;Inanc et al, 2014;Varol et al, 2014;Yadav et al, 2014). Pemetrexed is a novel multitargeted antifolate that inhibits several enzymes in the de novo pathways of pyrimidine and purine biosynthesis, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide ormyltransferase.…”